Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 02 2021 - 4:05PM
Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative, disease-modifying therapies for neurodegenerative
diseases, today announced that Richard Peters, M.D., Ph.D.,
President and Chief Executive Officer, will present at the H.C.
Wainwright Global Life Sciences Conference.
The presentation will be available on-demand via the conference
portal and through the Company's website at yumanity.com/events
beginning March 9, starting at 7:00am EST.
About Yumanity TherapeuticsYumanity
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to accelerating the revolution in the treatment of
neurodegenerative diseases through its scientific foundation and
drug discovery platform. The Company’s most advanced product
candidate, YTX-7739, is currently in Phase 1 clinical development
for Parkinson’s disease. Yumanity’s drug discovery platform is
designed to enable the Company to rapidly screen for potential
disease-modifying therapies by overcoming toxicity of misfolded
proteins in neurogenerative diseases. Yumanity’s pipeline consists
of additional programs focused on Lewy body dementia, multi- system
atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s
disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s
disease. For more information, please visit
www.yumanity.com.
ContactsInvestors:Burns
McClellan, Inc.John Grimaldijgrimaldi@burnsmc.com (212)
213-0006
Media:Burns McClellan, Inc.Ryo Imai / Robert
Flamm, Ph.D.rimai@burnsmc.com / rflamm@burnsmc.com (212)
213-0006
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024